Protective role of melatonin in progesterone production by human luteal cells.
Study Goal
The researchers aimed to determine whether melatonin protects luteinized granulosa cells from oxidative stress and enhances progesterone production during ovulation.
Results Summary
Melatonin concentrations in follicular fluid were positively correlated with progesterone levels and negatively correlated with oxidative stress markers. Melatonin treatment reversed the inhibitory effect of H₂O₂ on progesterone production and improved serum progesterone levels in women with luteal phase defects.
Population
Women undergoing in vitro fertilization and embryo transfer (IVF-ET), including a subgroup with luteal phase defects.
Effective Dosage
3 mg/day at 22:00 hr (clinical trial); 1, 10, 100 μg/mL (in vitro).
Duration
Throughout the luteal phase (clinical trial); duration of in vitro incubation not specified.
Interactions
None mentioned
| Intervention | Direction | Endpoint | Population | Dosage | Impact | Claim # |
|---|---|---|---|---|---|---|
melatonin | increase | progesterone concentrations | women undergoing in vitro fertilization and embryo transfer (IVF-ET) | r = 0.342, P < 0.05 | were positively correlated with | #1 |
melatonin concentrations | decrease | concentration of 8-hydroxy-2'-deoxyguanosine (8-OHdG), an oxidative stress marker | women undergoing in vitro fertilization and embryo transfer (IVF-ET) | r = -0.342, P < 0.05 | were negatively correlated with | #2 |
H(2)O(2) | decrease | progesterone production by luteinized granulosa cells | luteinized granulosa cells | - | significantly inhibited | #3 |
melatonin treatment | increase | progesterone production by luteinized granulosa cells | luteinized granulosa cells | - | overcame the inhibitory effect of | #4 |
melatonin (3 mg/day at 22:00 hr) | increase | serum progesterone concentrations (>10 ng/mL during the mid-luteal phase) | women with luteal phase defect | nine of 14 women (64.3%) | improved | #5 |
This study investigated whether melatonin protects luteinized granulosa cells from reactive oxygen species (ROS) as an antioxidant to enhance progesterone production in the follicle during ovulation. Follicular fluid was sampled at the time of oocyte retrieval in women undergoing in vitro fertilization and embryo transfer (IVF-ET). Melatonin concentrations in the follicular fluid were positively correlated with progesterone concentrations (r = 0.342, P < 0.05) and negatively correlated with the concentration of 8-hydroxy-2'-deoxyguanosine (8-OHdG), an oxidative stress marker (r = -0.342, P < 0.05). The progesterone and 8-OHdG concentrations were negatively correlated (r = -0.246, P < 0.05). Luteinized granulosa cells were obtained at the time of oocyte retrieval in women undergoing IVF-ET. Cells were incubated with H(2)O(2) (30, 50, 100 μm) in the presence or absence of melatonin (1, 10, 100 μg/mL). Progesterone production by luteinized granulosa cells was significantly inhibited by H(2)O(2). Melatonin treatment overcame the inhibitory effect of H(2) O(2) . Twenty-five patients who had luteal phase defect (serum progesterone concentrations <10 ng/mL during the mid-luteal phase) were divided into two groups during the next treatment cycle: 14 women were given melatonin (3 mg/day at 22:00 hr) throughout the luteal phase and 11 women were given no medication as a control. Melatonin treatment improved serum progesterone concentrations (>10 ng/mL during the mid-luteal phase) in nine of 14 women (64.3%), whereas only two of 11 women (18.1%) showed normal serum progesterone levels in the control group. In conclusion, melatonin protects granulosa cells undergoing luteinization from ROS in the follicle and contributes to luteinization for progesterone production during ovulation.